10x Genomics Offerings Not Yet Big Enough to Offset Core Business Deceleration - GS
Tweet Send to a Friend
Goldman Sachs analyst Matthew Sykes downgraded shares of 10x Genomics (NASDAQ: TXG) to Sell from Neutral in a note Thursday ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
